Navigation Links
OncoGenex Announces Publication of Custirsen Phase II Clinical and Pre-Clinical Data in Leading Cancer Journals
Date:9/6/2011

BOTHELL, Wash. and VANCOUVER, British Columbia, Sept. 6, 2011 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that data from two studies, a Phase II clinical study and a pre-clinical study, evaluating the investigational compound custirsen (OGX-011/TV-1011), were published in the September issues of the journals Clinical Cancer Research and Cancer Research.

Custirsen inhibits the production of clusterin, a protein commonly over-produced in cancer cells and a cause of treatment resistance. Two Phase III studies evaluating custirsen in men with castrate-resistant prostate cancer (CRPC) are ongoing: the SYNERGY clinical trial - designed to evaluate an overall survival benefit for custirsen in combination with first-line docetaxel treatment, and the Prostate Cancer SATURN Trial - which will evaluate a durable pain palliation benefit in patients receiving second-line chemotherapy. Both studies are currently enrolling CRPC patients.

Phase II Data Published in Clinical Cancer Research

Data from a Phase II clinical study of custirsen in combination with docetaxel retreatment or mitoxantrone as second-line chemotherapy in patients with metastatic castrate-resistant prostate cancer (mCRPC) was published in the September 1, 2011 issue of Clinical Cancer Research.

In the clinical study, custirsen combined with docetaxel retreatment resulted in overall survival of 15.8 months. When custirsen was combined with mitoxantrone, overall survival was 11.5 months. The Phase II study also evaluated pain responses in patients with mCRPC. Overall, the pain response was durable (greater than or equal to three months) in 88 percent of patients who had pain or were on opioids for pain at study entry.

"These are encouraging results because we observed durable pain responses in many patients who had di
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer
2. OncoGenex Reports Third Quarter Financial Results
3. OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering
4. OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
5. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
6. OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum
7. TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER
8. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
9. OncoGenex Reports Second Quarter Financial Results
10. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
11. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Massachusetts (PRWEB) October 22, 2014 ... announced the release of a new infographic, Understanding ... to create a beautifully designed, easy to follow informative ... transmission, areas of outbreak, symptoms and prevention. , "As ... discovered that the 2014 Ebola outbreak represents not only ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Currently ... Sartorius, A & D Weighing, Rice Lake, and ... Semi-Micro Balance . The Sartorius CPA Semi-Micro Balance ... affordable high-quality, precise, and user-friendly laboratory balance. , ... laboratory equipment, their laboratory balances are well known ...
(Date:10/22/2014)... Hill, SC (PRWEB) October 22, 2014 ... expansion of its cardiovascular pharmacogenetics menu, which enables ... patient outcomes. With PCLS’s evidence-based results, healthcare ... needs and optimize their therapy, while minimizing risks ... In the U.S., according to the FDA [1] ...
(Date:10/22/2014)... Oct. 22, 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, announced today that ... Notice of Allowance for a composition of matter patent ... difficile program, SYN-004. This is Synthetic Biologics, first ... U.S. and adds to the Company,s extensive C. ...
Breaking Biology Technology:Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4
... 2010 Shire plc (LSE: SHP,NASDAQ: SHPGY ) the global specialty biopharmaceutical company, announces,results for the three months to March 31, 2010 . ... ... $718 million ... Total revenues ...
... , April 29, 2010 According to ... by,MarketsandMarkets ( http://www.marketsandmarkets.com ), The global oncology,biomarker market is ... 2009 to $9.5,billion in 2014 at a ... Oncology,Biomarkers Market report analyzes the oncology biomarkers diagnostics and,discovery ...
... also known as hypertension, is a serious health risk factor ... the molecular basis of the disease remains poorly understood. ... ( www.genome.org ), scientists have sequenced the genome of ... variants that will help researchers to understand causes of the ...
Cached Biology Technology:Shire's Replenished Portfolio Drives Excellent Quarterly Performance 2Shire's Replenished Portfolio Drives Excellent Quarterly Performance 3Shire's Replenished Portfolio Drives Excellent Quarterly Performance 4Shire's Replenished Portfolio Drives Excellent Quarterly Performance 5Shire's Replenished Portfolio Drives Excellent Quarterly Performance 6Shire's Replenished Portfolio Drives Excellent Quarterly Performance 7Shire's Replenished Portfolio Drives Excellent Quarterly Performance 8Shire's Replenished Portfolio Drives Excellent Quarterly Performance 9Shire's Replenished Portfolio Drives Excellent Quarterly Performance 10Shire's Replenished Portfolio Drives Excellent Quarterly Performance 11Shire's Replenished Portfolio Drives Excellent Quarterly Performance 12Shire's Replenished Portfolio Drives Excellent Quarterly Performance 13Shire's Replenished Portfolio Drives Excellent Quarterly Performance 14Shire's Replenished Portfolio Drives Excellent Quarterly Performance 15Shire's Replenished Portfolio Drives Excellent Quarterly Performance 16Shire's Replenished Portfolio Drives Excellent Quarterly Performance 17Shire's Replenished Portfolio Drives Excellent Quarterly Performance 18Shire's Replenished Portfolio Drives Excellent Quarterly Performance 19Shire's Replenished Portfolio Drives Excellent Quarterly Performance 20Shire's Replenished Portfolio Drives Excellent Quarterly Performance 21Shire's Replenished Portfolio Drives Excellent Quarterly Performance 22Shire's Replenished Portfolio Drives Excellent Quarterly Performance 23Shire's Replenished Portfolio Drives Excellent Quarterly Performance 24Shire's Replenished Portfolio Drives Excellent Quarterly Performance 25Shire's Replenished Portfolio Drives Excellent Quarterly Performance 26Shire's Replenished Portfolio Drives Excellent Quarterly Performance 27Shire's Replenished Portfolio Drives Excellent Quarterly Performance 28Shire's Replenished Portfolio Drives Excellent Quarterly Performance 29Shire's Replenished Portfolio Drives Excellent Quarterly Performance 30Shire's Replenished Portfolio Drives Excellent Quarterly Performance 31Shire's Replenished Portfolio Drives Excellent Quarterly Performance 32Shire's Replenished Portfolio Drives Excellent Quarterly Performance 33MarketsandMarkets: Global Oncology Biomarkers Market Worth US$9.5 Billion by 2014 2MarketsandMarkets: Global Oncology Biomarkers Market Worth US$9.5 Billion by 2014 3MarketsandMarkets: Global Oncology Biomarkers Market Worth US$9.5 Billion by 2014 4
(Date:10/16/2014)... have challenged conventional thinking on how the bowel lining ... for how bowel cancer starts. , The researchers produced ... regenerating the ,crypts, that are a feature of the ... in bowel cancer development, a controversial finding as scientists ... Using 3D imaging technologies, Dr Chin Wee Tan and ...
(Date:10/16/2014)... Virus causes severe respiratory tract infections and worldwide ... Scientists at VIB and Ghent University have succeeded ... this common virus infection. , Xavier Saelens ... paves the way for the development of a ... that causes suffering in numerous small children and ...
(Date:10/16/2014)... October 16, 2014 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... technologies including Wocket™, the Smart Wallet, at the 13 ... is a leading global conference on the intersection of ... Mark Anderson , founder and publisher of the ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2New perspectives for development of an RSV vaccine 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3
... Researchers from LSU Health Sciences Center New Orleans ... of Child Health and Human Development (NICHD), Harvard School ... Medical School, have found for the first time that ... a week prior to pregnancy appears to significantly elevate ...
... - The inaugural Global Conference on Systems & ... Washington, DC, focuses on the convergence of complex large-scale ... The goal of the conference ... targeted complex systems, examined by domain, each successive year. ...
... early bird registration rates and register online now for ... WHAT: IOF WCO-ECCEO10 is a joint ... European Society for Clinical and Economic Aspects of Osteoporosis ... the world are expected to attend. The exciting scientific ...
Cached Biology News:Sugary cola drinks linked for first time to higher risk of gestational diabetes 2Sugary cola drinks linked for first time to higher risk of gestational diabetes 3First global conference on systems and enterprises at new Stevens location, Washington, DC, Dec. 3-4 2
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to KLH (Keyhole Limpet Hemocyanin) lysine through amide bonds....
Estrogen Receptor (ER) Competitor Assay Kits Green for Estrogen Receptors-alpha and -beta (ER-Alpha and ER-Beta) are ideal for screening novel estrogen receptor binding compounds and endocrine disrup...
Human Aminopeptidase P2/XPNPEP2 Affinity Purified PAb ENTREZ GeneID: 7512...
in vitro Translation, Accessory Products...
Biology Products: